RVMD vs VRTX
Revolution Medicines, Inc. and Vertex Pharmaceuticals, both Healthcare
Vertex Pharmaceuticals is the larger company at $115B against $35B. Over the past year RVMD returned +517% against +42% for VRTX. Ryufin's sector-relative Smart Score puts RVMD ahead, 10/10 against 8/10.
| Figure | RVMD | VRTX |
|---|---|---|
| Last close | $216 | $547 |
| Market cap | $35B | $115B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 31.9 |
| 1-year return | +517% | +42% |
| 5-year return | +635% | +171% |
| Ryufin Smart Scoresector-relative, 1–10 | 10/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Revolution Medicines, Inc.
Vertex Pharmaceuticals
Revenue of $3.3B in Q2 2026, net income $1.1B. Its largest reported line is TRIKAFTAKAFTRIO, 79% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.